Compare Ascendis Pharma A/S (ASND) vs CubeSmart (CUBE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs CubeSmart — how do they compare? Ascendis Pharma A/S trades at $264.3 (market cap $17.74B), while CubeSmart trades at $40.42 (market cap $9.10B). The key difference: Ascendis Pharma A/S is the larger of the two by market cap, and CubeSmart pays a 5.27% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | CUBE | |
|---|---|---|
Market Cap | $17.74B | $9.10B |
Sector | Health | Real Estate |
52-Week High | $277.18 | $42.34 |
52-Week Low | $163.32 | $35.36 |
Enterprise Value | $18.11B | $12.60B |
Dividend Yield | — | 5.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
CubeSmart (CUBE) trades at $40.19, up 1.01% with a bearish technical signal despite recent earnings beats. The REIT maintains strong profitability with 28.93% net margins and offers a 5.3% dividend yield. Analyst consensus shows mixed sentiment with 41% buy ratings but a $43.86 price target suggesting 9% upside. Recent news highlights Q2 2026 earnings anticipation on July 30, 2026, while institutional investors have been trimming positions.
The stock presents value with reasonable valuation multiples (P/E 28.1, P/S 8.13) and consistent cash flow generation, though high debt levels and interest rate sensitivity pose risks. Near-term performance will depend on Q2 earnings results and macroeconomic conditions affecting the self-storage sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About CubeSmart
CubeSmart is a real estate investment trust that acquires, owns, and manages self-storage facilities throughout the United States. The company's real estate portfolio is composed of buildings with numerous enclosed storage areas for both residential and commercial customers to rent mainly on a month-by-month basis. Most of CubeSmart's facilities are located in Florida, Texas, California, New York, and Illinois. Cumulatively, these states account for both the majority of the square footage in the company's real estate portfolio and the majority of its revenue. CubeSmart derives nearly all of its revenue from rental income from tenants utilizing its storage facilities.
Read more on CUBE →
